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ross-cultural  comparisons  of  medicinal  ﬂoras  and  bioprospecting  revisitedProfessor Gertsch raises interesting points in his wide-ranging
ommentary on our recent publication (Saslis-Lagoudakis et al.,
011a). We  welcome the opportunity to explore the points he
aises. Speciﬁcally, we address the question he poses, “what exactly
re the implications for bioprospecting strategies suggested by this
tudy?”
As we noted, and Gertsch further emphasises, ethnomedicinal
nformation has performed poorly as a criterion to increase the
it-rate of screening programmes. Furthermore, pharmaceutical
ompanies have cut back on their use of natural products in drug
iscovery (Harvey, 2008). From this perspective, it is unrealistic
o expect that any studies of traditional medicine, cross-cultural or
therwise, will play a signiﬁcant and immediate role in the develop-
ent of modern pharmaceuticals. However, though “big-pharma”
as stepped back from natural product research there is still a
ole for natural products in traditional approaches to drug discov-
ry. Harvey describes traditional approaches as those “making use
f material that has been found by trial and error over many years
n different cultures and systems of medicine” (Harvey, 1999). This
ind of exploitation of traditionally used plants continues apace
n many countries with limited access to modern pharmaceuticals.
he examples of ongoing programmes of screening plants for bio-
ogical activity based on traditional knowledge of use are far too
umerous to list. On Professor Gertsch’s own website there is a
ost from the Director of an Indian phyto-pharmaceutical com-
any which describes a research strategy for product development
ased on ethnopharmacological data and in vitro screen-
ng (http://gertschgroup.com/forum/topic/7571?page=1#message
5541; accessed 07/08/11). So, whilst they may  not be included in
trategies of big pharmaceutical companies, plants that have been
found by trial and error over many years in different cultures and
ystems of medicine” (Harvey, 1999) remain a source of novel prod-
cts. This research is stimulated, no doubt, by the fact that up to 80%
f compounds obtained from plants and used as drugs are used in
greement with the ethnomedicinal use of the plant they were iso-
ated from (Fabricant and Farnsworth, 2001). It is in this context
hat we argue our study has implications for bioprospecting.
Our study provides some indirect measure of the efﬁcacy of
raditional medicines that can assist prioritise plant taxa for bio
fﬁcacy screening. Acceptance of plant medicine, whether through
ovel product development or the promotion of local health tra-
itions, hinges on efﬁcacy. Yet efﬁcacy has been demonstrated for
ess than 15% of plant species that have to date been subjected to
linical trials (Soejarto et al., 2005). We  argue that cross-cultural
tudies can provide indirect evidence of efﬁcacy without the clin-
cal trials, which are unlikely to be possible on a large scale.
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Open access under CC BY-NC-ND license.Screening for bioactivity identiﬁes plants with a biological basis
for their efﬁcacy, but plant medicines used traditionally may  be
efﬁcacious for contextual reasons. Cross-cultural studies can tease
apart the set of plants used because of their “meaning response”,
but without biological efﬁcacy, from the set with biological efﬁcacy.
In our study we  minimise the likelihood that cultural transfer (i.e.
the horizontal transmission of “meaning” between cultures) and
the independent derivation of meaning (e.g. independent “discov-
ery” of the “contextual value” of “showy and fragrant” plants), by
sampling three extremely different ﬂoras, geographically distant
from each other, and exploited in widely contrasting systems of
traditional medicine by distantly related peoples. In this way our
study forms part of a literature, which seeks to explain why eth-
nomedicinal information has performed poorly in high-throughput
screens. In other words, we make some steps to understand how the
“overestimation of the predictive value of ethnopharmacopoeias in
bioprospecting”, referred to by Gertsch, can be overcome. Like other
studies (Bletter, 2007), we  argue that cross-cultural comparison can
provide evidence of independent discovery. The hot groups dis-
covered through cross-cultural comparison are indeed the plants
that have been “found by trial and error over many years in different
cultures and systems of medicine”. There is evidence that prioriti-
sation of plant species based on the criterion of cross-cultural use
is an effective bioscreening strategy (Li et al., 2003). Ventures that
identify ethnopharmacologically promising plant subjects based on
their prominence in different ethnopharmacopoeias are underway
(Molander et al., submitted for publication). Additionally, similar
approaches are likely to highlight taxa that produce a wide vari-
ety of pharmacologically active compounds (Douwes et al., 2008)
hence likely to indirectly bring to surface previously overlooked
taxa with complex phytochemistry.
Our study highlights the present limitations of cultural com-
parisons, which might be overcome using novel approaches, to
increase the value of ethnomedicinal information. We  have already
developed new tools that use plant phylogenetic information to
interpret cross-cultural plant use (Saslis-Lagoudakis et al., 2011b)
and we  have applied this approach to the same ﬂoras (Saslis-
Lagoudakis et al., in prep.), allowing the identiﬁcation of lineages
that show cross-cultural agreement in use, thus addressing other
concerns raised by Gertsch with regards to the ideal taxonomic
level at which a study like this should be carried out.
Gertsch notes that the logical implication of our ﬁndings is that
bioprospectors should focus on screening the medicinal plants in
hot families. Although he makes fun of this strategy, we  argue that
it is a good one for the rational prioritisation of plant taxa for
local ethnopharmacological studies and bioprospecting schemes,
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bioprospecting: Issues on intellectual property and beneﬁt-sharing. Journal of
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nd one we would recommend. He notes that the analyses con-
ucted in our study are biased towards large families. This might
e true for regression analyses (Bennett and Husby, 2008; Weckerle
t al., 2011), but Gertsch overlooks that we also performed the bino-
ial analysis approach proposed by Bennett and Husby (2008) that
vercomes this problem. Indeed, several smaller families, such as
nacardiaceae, Clusiaceae, Convolvulaceae and Sapotaceae appear
n our list of hot families. Gertsch also overlooks that in the analy-
es performed for speciﬁc categories of use – the type of analyses
hat could be the most informative for bioprospecting – several
mall families were recovered: Argophyllaceae, Ephedraceae, Pit-
osporaceae, Podocarpaceae, just to name a few. We  agree that
ighlighting large families such as Asteraceae and Rubiaceae may
ot, on the face of it, speed screening. Gertsch picks Asteraceae as
n example of a “hot” family we identify, and states “we already
now Asteraceae are important”. Yes, we agree that Asteraceae are
nown to be important, but what is “known” and what is proven
re not always coincident. For example, it is easy to ﬁnd state-
ents such as “The Fabaceae had the highest number (20) of species
ith alkaloids. . .As this would lead one to expect, this family con-
ains many medicinals that are highly regarded by Garifuna healers”
Coe and Anderson, 1996); the same publication refers to the family
abaceae as one of “the most important families”. On the surface of it,
his might lead an uncritical reader to consider the Fabaceae to be
 “hot” family – perhaps a reader might consider that “we already
now” Fabaceae are important. In fact our study, and other studies
f cross-cultural use, show that this family very seldom appears as a
hot” family given its species richness, and should not be prioritised.
ther equally large families, such as Orchidaceae, are indicated as of
igniﬁcantly lower traditional use, so discounting them will speed
creening.
Finally, we refer to a very interesting issue that Gertsch raises
hen stating “it is possible that the authors understand something
lse by bioprospecting than I do”. Deﬁnitions for bioprospect-
ng are numerous in the literature. Gertsch provides one from
he molecular scientist’s perspective, as “the process of discovery
f bioactive principles or biogenetic materials from natural sources”
nd other authors have given similar deﬁnitions. For example,
he objective of bioprospecting has been deﬁned as “searching for
ew biologically active chemicals in organisms”  (Firn, 2003), or as
the systematic search for, and the development of, new sources of
hemical compounds, genes, micro- and macroorganisms, and other
conomically valuable biological products” (Makhubu, 1998). The lat-
er deﬁnition allows for a broader end product for bioprospecting
han molecular advances only, a view that has been supported
y other authors that deﬁne bioprospecting as “the search for
alue in the biological world” (McClatchey, 2005) or “any of sev-
ral efforts supporting new potential lead identiﬁcation from natural
ources” (Buenz et al., 2004). There are also several studies that
efer to bioprospecting as the added value for humanity from
iological conservation. For example, bioprospecting as “the sys-
ematic search for new commercial applications for biota” (Barrett
nd Lybbert, 2000) makes special reference to biota. It becomes
lear form these few examples that the end product of bioprospect-
ng is different for different groups of researchers. For some it
s molecular advances that can be used commercially and for
thers it is the better understanding of the value of the natural
orld.
On no account do we discount the important research conducted
y Professor Gertsch and numerous colleagues around the globe.
n fact, we support it and believe it can potentially lead to ground-
reaking pharmacological innovations. However, we  believe that
he end product of such research has a different target group
han that of studies similar to ours. As the WHO  reports, 80%
f the population in developing countries depend on traditional
edicine for healthcare (WHO, 2008). For this majority of thecology 139 (2012) 688– 690 689
world’s population it will take years before “molecular” innovations
and patents permeate their healthcare. On the contrary, develop-
ing better understandings of the patterns of successful traditional
medicines and promoting their uses as traditional medicines can
improve local community healthcare and thus have a more imme-
diate end product for those that are most in need for it. Hence,
bioprospecting can serve different purposes – that are comple-
mentary rather than conﬂicting – for different parts of the world’s
population.
Our intention was  to contribute to the debate on the relation
between ethnobotanical knowledge and drug discovery. We  car-
ried out an experiment using carefully selected, speciﬁc ﬂoras for
the reasons stated above. We  welcome more similar studies using
the tools we have applied, as well as novel ones that appear in the
literature (Saslis-Lagoudakis et al., 2011b; Weckerle et al., 2011)
and we encourage such comparisons to be made between areas
that have had minimal cultural exchange. We strongly believe that
such comparisons will inform bioprospecting strategies and, most
importantly, will contribute to the understanding of traditional
medicine itself.
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